CHARACTERIZATION OF NUCLEOLAR ORGANIZER REGIONS IN CELLS OF TRANSMISSIBLE VENEREAL TUMOR IN CANINE: HISTOCHEMICAL STUDY

El objetivo del presente estudio fue visualizar y caracterizar las Regiones Organizadoras Nucleolares Argénticas (AgNORs) en células neoplásicas del tumor venéreo transmisible (TVT) de caninos a través de la impregnación con nitrato de plata. Se trabajó con una muestra tomada al azar de tejido parafinado de 30 caninos diagnosticados histológicamente (con coloración de Hematoxilina y Eosina) como TVT canino entre el 2000 al 2006. En 100 células por muestra se visualizó la presencia y ubicación de los AgNORs en las células neoplásicas. Se encontró un número medio de AgNORs por célula de 1.53, por núcleo de 0.91 y por nucléolo de 0.62. La distribución de los AgNORs en el total de células evaluadas fue de 60.7% (1821/3000) en el núcleo, 34.3% (1029/3000) en el nucléolo y 5% (150/3000) en ambas estructuras.The objective of the present study was to visualize and characterize the Nucleolar Organizer Regions (AgNORs) in Cells of Transmissible Venereal Tumor (TVT) in the canine through the impregnation with silver nitrate. One sample was collected at random from paraffin tissue of 30 canine tissue samples that were histological diagnosed (using Hematoxylin and Eosin stain) as TVT during the period of 2000-2006. The AgNORs were visualized and localized in 100 cells per sample. The average number of AgNORs per cell was 1.53, per cell nucleus was 90.91 and per nucleolus was 0.62. The distribution of AgNORs in the total number of cells was 60.7% (1821/ 3000) in the nucleus, 34.3% (1029/3000) in the nucleolus, and 5% (150/3000) in both structures

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events